



FibroGen Provides Additional Information on Roxadustat

April 5, 2021

Roxadustat Cardiovascular Safety Results

| | Analyses with post-hoc stratification factors | Analyses with pre-specified stratification factors |
|---|---|--|
| | HR (95% Confidence Interval) | HR (95% Confidence Interval) |
| Non Dialysis (OLYMPUS, ANDES, ALPS N=4,270); ITT | | |
| MACE | 1.08 (0.94, 1.24) | 1.10 (0.96, 1.27) |
| MACE+ | 1.04 (0.91, 1.18) | 1.07 (0.94, 1.21) |
| ACM | 1.06 (0.91, 1.23) | 1.08 (0.93, 1.26) |
| Dialysis Dependent (HIMALAYAS, SIERRAS, ROCKIES N=3,880); OT-7 | | |
| MACE | 0.96 (0.82, 1.13) | 1.02 (0.88, 1.20) |
| MACE+ | 0.86 (0.74, 0.98) | 0.91 (0.80, 1.05) |
| ACM | 0.96 (0.79, 1.17) | 1.02 (0.84, 1.23) |
| Incident Dialysis (N=1,526); OT-7 | | |
| MACE | 0.70 (0.51, 0.96) | 0.82 (0.60, 1.11) |
| MACE+ | 0.66 (0.50, 0.89) | 0.78 (0.59, 1.02) |
| ACM | 0.76 (0.52, 1.11) | 0.82 (0.57, 1.18) |

ITT - intention to treat with long-term follow up

OT-7 - on-treatment plus 7 days

Major Adverse Cardiovascular Event (MACE) - a composite endpoint of all-cause mortality, stroke, and myocardial infarction. (MACE+) - in addition to the components in MACE, includes hospitalization due to heart failure or unstable angina. (ACM) - all-cause mortality.

The background is a dark blue color. On the right side, there are several abstract geometric shapes in a lighter shade of blue. These include two small circles near the top, a thick diagonal line crossing the frame from the top right to the bottom left, and several other lines of varying thicknesses and orientations, some intersecting each other.

Thank You

For more information contact at mtung@fibrogen.com